Bioequivalence Study of 3 mg Glimepiride Tablet in Indonesia Healthy Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

34 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-09-21

Study Completion Date

2021-01-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study was conducted toinvestigate whether the bioavailability of 3 mg Glimepiride Tablet Manufactured by PT. Harsen Laboratories was bioequivalent to the reference product, 3 mg Amaryl® Tablet Manufactured by PT. Aventis Indonesia Pharma, Indonesia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bioequivalence Study of 4 mg Glimepiride Tablet

NCT01677247

Glimepiride BE Study in Healthy Volunteers Under Fasting Condition

COMPLETED NA

COMPOUND (INN): HOE490O - GLIMEPIRIDE / METFORMIN HCl (Amaryl® M)0 (Glimepiride/Metformin Hydrochloride Immediate Release Combination Tablet) in Fed Conditions in Healthy Male and/or Female Subjects.

NCT02395237

Healthy

WITHDRAWN PHASE1

ADIponectin and Asymmetric Dimethylarginine (ADMA) Level in Type-2 Diabetes Patients After 12 Weeks of Treatment With GlimepiRide And Metformin Fixed Dose Combination

NCT01204580

Diabetes Mellitus, Type 2

COMPLETED PHASE4

Dose Proportionality Study Comparing Amaryl-M 1/500 mg and Amaryl-M 2/500 mg

NCT00934817

Healthy

COMPLETED PHASE1

Glimepiride 4 mg Tablets Under Non-Fasting Conditions

NCT00835172

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study was conducted following an oral administration of one tablet of the test drug (3 mg Glimepiride Tablet) or one tablet of the reference drug (3 mg Amaryl® Tablet ). Blood samples were drawn before dosing (0 h) and at 15, 30, 45 minutes, and 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 9, 12, 18, 24, and 30 hours after drug administration. The entire subjects were given 60 mL of 20% glucose solution to minimize hypoglycemic effects at 15, 30, 45 minutes, and 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75 and 4 hours after drug administration. Following a washout period of one week, this procedure was repeated using the alternate drug. The plasma concentrations of glimepiride were determined by means of LC-MS/MS system. The LLOQ is 1.99 ng/mL of glimepiride. The pharmacokinetic parameters used in this study were area under the concentration-time curve of glimepiride from time zero to 30 hours (AUCt), area under the concentration-time curve from time zero to infinite (AUCinf), maximum concentration (Cmax), time required to reach the maximum concentration (tmax) and the elimination half life (t½).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Drug Use

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Randomized, single blind, two-period, single dose, cross-over study with one week washout period under fasted condition

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Glimepiride 3 mg Tablet

Participants received Glimepiride 3 mg Tablet with 240 mL of 20% glucose solution

Group Type EXPERIMENTAL

Glimepiride

Intervention Type DRUG

Glimepiride is a sulfonylurea, indicated as an adjunct to proper dietary management, exercise and weight reduction to lower the blood glucose in patients with type 2 diabetes whose hyperglycemia cannot be controlled by diet and exercise alone.

Amaryl® 3 mg tablet

Participants received Amaryl® 3 mg tablet (Glimepiride 3 mg) with 240 mL of 20% glucose solution

Group Type ACTIVE_COMPARATOR

Amaryl®

Intervention Type DRUG

Amaryl®

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Glimepiride

Glimepiride is a sulfonylurea, indicated as an adjunct to proper dietary management, exercise and weight reduction to lower the blood glucose in patients with type 2 diabetes whose hyperglycemia cannot be controlled by diet and exercise alone.

Intervention Type DRUG

Amaryl®

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* healthy male and female
* had read the subject information and signed informed consent documents
* were age between 18 to 55 years
* had body mass index between 18 to 25 kg/m2
* had a normal electrocardiogram
* had normal blood pressure (systolic was ranged between 90 to 120 mmHg and diastolic was ranged between 60 to 80 mmHg)
* had normal heart rate (ranged between 60 to 100 bpm)
* have no significant disease in medical history; have no significant abnormal values in laboratory and physical examination during screening
* had acceptance to use protection (condom) during intercourse with their spouse throughout the study

Exclusion Criteria

* Pregnant and/or nursing woman.
* Those with a history of contraindication or hypersensitivity to glimepiride, other antidiabetic agent or other ingredients in the study products or a history of serious allergic reaction to any drug, significant allergic disease or allergic reaction.
* Those with a history or presence of medical condition which might significantly influence the pharmacokinetics of the study drug, e.g. chronic gastrointestinal disease, diarrhea, gastric surgery, renal insufficiency, hepatic dysfunction or cardiovascular disease.
* Those with a history or presence of any coagulation disorder or clinically significant hematology abnormalities.
* Those who using any medication (prescription or non-prescription drug, food supplement, herbal medicine), particularly the medication known to affect the pharmacokinetic of the study drug, within one week prior to the drug administration day.
* Those who had participated in any clinical study within 3 months prior to the study (\< 90 days).
* Those who donated or lost 300 mL (or more) of blood within 3 months prior to the study.
* Those who smoked more than 10 cigarettes a day
* Those with a history of travelling to another city within the last 14 days
* Those with a history of direct contact with a COVID-19 positive person in the subject's neighborhood
* Those with a history or present of sore throat, fever (with temperature more than 37°C) or dyspnea within the last 14 days
* Those who reactive to anti SARS CoV-2 test
* Those who were positive to HIV, HBsAg, and HCV tests (to be kept confidential).
* Those with a history of drug or alcohol abused within 12 months prior to screening for this study
* Those who were unlikely to comply with the protocol, e.g uncooperative attitude, inability to return for follow up visits, poor venous access.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes